|Bid||15.95 x 900|
|Ask||16.70 x 1000|
|Day's Range||16.23 - 16.28|
|52 Week Range||13.59 - 16.82|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.86|
|Expense Ratio (net)||0.55%|
As global growth is expected to slow down further, investors can resort to safer options like treasury ETFs, dividend ETFs and quality picks.
Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1. The expectation is ~$3.82 billion compared to ~$3.7 billion for the third quarter of 2017.
Novartis (NVS) is a leading pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products.
Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.